vs

Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and Lucas GC Ltd (LGCL). Click either name above to swap in a different company.

Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $7.5M, roughly 1.9× Lucas GC Ltd). Lucas GC Ltd runs the higher net margin — 5.6% vs -342.3%, a 347.9% gap on every dollar of revenue.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.

GOSS vs LGCL — Head-to-Head

Bigger by revenue
GOSS
GOSS
1.9× larger
GOSS
$13.8M
$7.5M
LGCL
Higher net margin
LGCL
LGCL
347.9% more per $
LGCL
5.6%
-342.3%
GOSS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
GOSS
GOSS
LGCL
LGCL
Revenue
$13.8M
$7.5M
Net Profit
$-47.2M
$414.1K
Gross Margin
33.7%
Operating Margin
-333.6%
4.0%
Net Margin
-342.3%
5.6%
Revenue YoY
47.1%
Net Profit YoY
-43.0%
EPS (diluted)
$-0.21
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GOSS
GOSS
LGCL
LGCL
Q4 25
$13.8M
Q3 25
$13.3M
Q2 25
$7.5M
Q2 24
$95.8M
$11.5M
Q1 24
$0
Q3 23
$0
Q2 23
$0
Net Profit
GOSS
GOSS
LGCL
LGCL
Q4 25
$-47.2M
Q3 25
$-48.2M
Q2 25
$414.1K
Q2 24
$49.2M
$1.0M
Q1 24
$-41.9M
Q3 23
$-40.0M
Q2 23
$-42.5M
Gross Margin
GOSS
GOSS
LGCL
LGCL
Q4 25
Q3 25
Q2 25
33.7%
Q2 24
33.5%
Q1 24
Q3 23
Q2 23
Operating Margin
GOSS
GOSS
LGCL
LGCL
Q4 25
-333.6%
Q3 25
-369.4%
Q2 25
4.0%
Q2 24
54.3%
8.8%
Q1 24
Q3 23
Q2 23
Net Margin
GOSS
GOSS
LGCL
LGCL
Q4 25
-342.3%
Q3 25
-362.7%
Q2 25
5.6%
Q2 24
51.4%
8.9%
Q1 24
Q3 23
Q2 23
EPS (diluted)
GOSS
GOSS
LGCL
LGCL
Q4 25
$-0.21
Q3 25
$-0.21
Q2 25
$0.20
Q2 24
$0.22
$0.01
Q1 24
$-0.19
Q3 23
$-0.21
Q2 23
$-0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GOSS
GOSS
LGCL
LGCL
Cash + ST InvestmentsLiquidity on hand
$136.9M
$606.9K
Total DebtLower is stronger
Stockholders' EquityBook value
$-122.8M
$6.3M
Total Assets
$172.2M
$8.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GOSS
GOSS
LGCL
LGCL
Q4 25
$136.9M
Q3 25
$180.2M
Q2 25
$606.9K
Q2 24
$354.5M
$978.1K
Q1 24
$244.4M
Q3 23
$328.9M
Q2 23
$162.1M
Stockholders' Equity
GOSS
GOSS
LGCL
LGCL
Q4 25
$-122.8M
Q3 25
$-82.3M
Q2 25
$6.3M
Q2 24
$81.5M
$5.3M
Q1 24
$26.7M
Q3 23
$104.6M
Q2 23
$-62.8M
Total Assets
GOSS
GOSS
LGCL
LGCL
Q4 25
$172.2M
Q3 25
$208.8M
Q2 25
$8.8M
Q2 24
$373.4M
$7.8M
Q1 24
$259.4M
Q3 23
$347.9M
Q2 23
$181.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GOSS
GOSS
LGCL
LGCL
Operating Cash FlowLast quarter
$-48.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GOSS
GOSS
LGCL
LGCL
Q4 25
$-48.3M
Q3 25
$-36.2M
Q2 25
Q2 24
$116.3M
Q1 24
$-52.3M
Q3 23
$-34.5M
Q2 23
$-38.3M
Capex Intensity
GOSS
GOSS
LGCL
LGCL
Q4 25
0.0%
Q3 25
0.0%
Q2 25
Q2 24
0.0%
Q1 24
Q3 23
Q2 23
Cash Conversion
GOSS
GOSS
LGCL
LGCL
Q4 25
Q3 25
Q2 25
Q2 24
2.36×
Q1 24
Q3 23
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GOSS
GOSS

Segment breakdown not available.

LGCL
LGCL

Recruitment service$4.4M60%
Others$2.9M39%

Related Comparisons